Asset Details
Do you wish to reserve the book?
The relationship between urine output and time to methotrexate clearance in pediatric leukemia patients receiving high-dose methotrexate therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The relationship between urine output and time to methotrexate clearance in pediatric leukemia patients receiving high-dose methotrexate therapy
Do you wish to request the book?
The relationship between urine output and time to methotrexate clearance in pediatric leukemia patients receiving high-dose methotrexate therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The relationship between urine output and time to methotrexate clearance in pediatric leukemia patients receiving high-dose methotrexate therapy
2025
Overview
Background
High-dose methotrexate (HD-MTX) is a cornerstone of pediatric acute lymphoblastic leukemia (ALL) treatment but poses a risk for delayed clearance and associated toxicities. While hydration is standard to enhance methotrexate (MTX) excretion, the relationship between urine output (UO) and time to MTX clearance remains underexplored.
Methods
We conducted a retrospective study of pediatric ALL patients treated with HD-MTX at Chang Gung Memorial Hospital between August 2023 and February 2025. Patients were stratified into higher (H-UO) and lower urine output (L-UO) groups using a 5.0 mL/kg/hr cutoff. Clinical outcomes including time to MTX normalization, delayed MTX clearance, hospitalization duration, and use of adjunctive diuretics were analyzed.
Results
Thirty-nine patients were included. The H-UO group showed significantly faster MTX clearance (2.0 vs. 4.0 days,
P
= 0.0035), lower incidence of delayed clearance (18.2% vs. 70.6%,
P
= 0.0025), and shorter hospital stays (5.0 vs. 7.0 days,
P
= 0.019). Diuretic use was higher in the L-UO group, primarily as a reactive measure. No significant difference in MTX-related major toxicities was observed.
Conclusions
Higher UO is associated with more efficient time to MTX clearance and shorter hospitalization in pediatric ALL patients receiving HD-MTX. Prospective studies are warranted to optimize supportive care protocols.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Antimetabolites, Antineoplastic - administration & dosage
/ Antimetabolites, Antineoplastic - adverse effects
/ Antimetabolites, Antineoplastic - pharmacokinetics
/ Antimetabolites, Antineoplastic - urine
/ Biomedical and Life Sciences
/ Child
/ Delayed methotrexate clearance
/ Female
/ Health Promotion and Disease Prevention
/ Humans
/ Infant
/ Leukemia
/ Male
/ Methotrexate - administration & dosage
/ Methotrexate - adverse effects
/ Methotrexate - pharmacokinetics
/ Methotrexate - therapeutic use
/ Oncology
/ Patients
/ Pediatric acute lymphoblastic leukemia
/ Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
/ Precursor Cell Lymphoblastic Leukemia-Lymphoma - urine
/ Toxicity
/ Urine
